Reyvow

Product NDC: 0002-4491
Requested package NDC: 0002-4491-61
11-digit product format: 000024491
Labeler code: 0002
Product ID: 0002-4491_29f467c6-0365-4831-b4ce-9a0eefaf5896
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: lasmiditan
Dosage form: TABLET
Route: ORAL
Labeler: Eli Lilly and Company
Application: NDA211280
Marketing category: NDA
Marketing start: 2019-10-11
Marketing end: 2027-02-21
Substance: LASMIDITAN
Active strength: 100 mg/1
DEA schedule: CV
NDC exclude flag: No
Current FDA listing: Yes

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 1 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Reporting period	Source date
excluded package	package	0002-4491	0002-4491-61	D	Discontinued by firm		2026-10-05

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 3 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	RLD / RS	Approval date
N211280-001	REYVOW	LASMIDITAN SUCCINATE	EQ 50MG BASE	TABLET / ORAL	RLD	2020-01-31
N211280-002	REYVOW	LASMIDITAN SUCCINATE	EQ 100MG BASE	TABLET / ORAL	RLD	2020-01-31
N211280-003	REYVOW	LASMIDITAN SUCCINATE	EQ 200MG BASE	TABLET / ORAL	RLD	2020-12-18

Orange Book patents#

Current patent rows page 1 of 1 · 11 matching rows.

Application-product, Patent, Expiration table
Application-product	Patent	Expiration	Use code	Coverage / status	Submission date
N211280-001	7423050	2028-02-17	U-1719	Drug substance, Drug product	2020-02-25
N211280-001	12257246	2030-07-07	U-2718		2025-04-22
N211280-001	11053214	2037-12-05	U-1719	Drug substance, Drug product	2021-07-28
N211280-001	12071423	2040-07-06		Drug product	2024-09-20
N211280-002	7423050	2028-02-17	U-1719	Drug substance, Drug product	2020-02-25
N211280-002	12257246	2030-07-07	U-2718		2025-04-22
N211280-002	11053214	2037-12-05	U-1719	Drug substance, Drug product	2021-07-28
N211280-002	12071423	2040-07-06		Drug product	2024-09-20
N211280-003	7423050	2028-02-17	U-1719	Drug substance, Drug product	2021-07-28
N211280-003	12257246	2030-07-07	U-2718		2025-04-22
N211280-003	11053214	2037-12-05	U-1719	Drug substance, Drug product	2021-07-28

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 115 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	RLD / RS	Approval date	Source SHA-256
2026-09-14 22:38:34	2026-08	N211280-001	REYVOW	EQ 50MG BASE	TABLET / ORAL	RLD	2020-01-31	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N211280-002	REYVOW	EQ 100MG BASE	TABLET / ORAL	RLD	2020-01-31	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N211280-003	REYVOW	EQ 200MG BASE	TABLET / ORAL	RLD	2020-12-18	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N211280-001	REYVOW	EQ 50MG BASE	TABLET / ORAL	RLD	2020-01-31	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N211280-002	REYVOW	EQ 100MG BASE	TABLET / ORAL	RLD	2020-01-31	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N211280-003	REYVOW	EQ 200MG BASE	TABLET / ORAL	RLD	2020-12-18	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N211280-001	REYVOW	EQ 50MG BASE	TABLET / ORAL	RLD	2020-01-31	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N211280-002	REYVOW	EQ 100MG BASE	TABLET / ORAL	RLD, RS	2020-01-31	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N211280-003	REYVOW	EQ 200MG BASE	TABLET / ORAL	RLD	2020-12-18	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N211280-001	REYVOW	EQ 50MG BASE	TABLET / ORAL	RLD	2020-01-31	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N211280-002	REYVOW	EQ 100MG BASE	TABLET / ORAL	RLD, RS	2020-01-31	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N211280-003	REYVOW	EQ 200MG BASE	TABLET / ORAL	RLD	2020-12-18	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N211280-001	REYVOW	EQ 50MG BASE	TABLET / ORAL	RLD	2020-01-31	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N211280-002	REYVOW	EQ 100MG BASE	TABLET / ORAL	RLD, RS	2020-01-31	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N211280-003	REYVOW	EQ 200MG BASE	TABLET / ORAL	RLD	2020-12-18	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N211280-001	REYVOW	EQ 50MG BASE	TABLET / ORAL	RLD	2020-01-31	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N211280-002	REYVOW	EQ 100MG BASE	TABLET / ORAL	RLD, RS	2020-01-31	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N211280-003	REYVOW	EQ 200MG BASE	TABLET / ORAL	RLD	2020-12-18	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N211280-001	REYVOW	EQ 50MG BASE	TABLET / ORAL	RLD	2020-01-31	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N211280-002	REYVOW	EQ 100MG BASE	TABLET / ORAL	RLD, RS	2020-01-31	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N211280-003	REYVOW	EQ 200MG BASE	TABLET / ORAL	RLD	2020-12-18	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N211280-001	REYVOW	EQ 50MG BASE	TABLET / ORAL	RLD	2020-01-31	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N211280-002	REYVOW	EQ 100MG BASE	TABLET / ORAL	RLD, RS	2020-01-31	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N211280-003	REYVOW	EQ 200MG BASE	TABLET / ORAL	RLD	2020-12-18	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N211280-001	REYVOW	EQ 50MG BASE	TABLET / ORAL	RLD	2020-01-31	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N211280-002	REYVOW	EQ 100MG BASE	TABLET / ORAL	RLD, RS	2020-01-31	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N211280-003	REYVOW	EQ 200MG BASE	TABLET / ORAL	RLD	2020-12-18	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N211280-001	REYVOW	EQ 50MG BASE	TABLET / ORAL	RLD	2020-01-31	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N211280-002	REYVOW	EQ 100MG BASE	TABLET / ORAL	RLD, RS	2020-01-31	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N211280-003	REYVOW	EQ 200MG BASE	TABLET / ORAL	RLD	2020-12-18	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N211280-001	REYVOW	EQ 50MG BASE	TABLET / ORAL	RLD	2020-01-31	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N211280-002	REYVOW	EQ 100MG BASE	TABLET / ORAL	RLD, RS	2020-01-31	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N211280-003	REYVOW	EQ 200MG BASE	TABLET / ORAL	RLD	2020-12-18	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	N211280-001	REYVOW	EQ 50MG BASE	TABLET / ORAL	RLD	2020-01-31	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N211280-002	REYVOW	EQ 100MG BASE	TABLET / ORAL	RLD, RS	2020-01-31	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N211280-003	REYVOW	EQ 200MG BASE	TABLET / ORAL	RLD	2020-12-18	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N211280-001	REYVOW	EQ 50MG BASE	TABLET / ORAL	RLD	2020-01-31	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N211280-002	REYVOW	EQ 100MG BASE	TABLET / ORAL	RLD, RS	2020-01-31	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N211280-003	REYVOW	EQ 200MG BASE	TABLET / ORAL	RLD	2020-12-18	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N211280-001	REYVOW	EQ 50MG BASE	TABLET / ORAL	RLD	2020-01-31	`301d65b070ca…`

Observed Orange Book patent history#

Patent history page 1 of 8 · 316 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Patent	Expiration	Use code	Coverage / status	Submission date	Source SHA-256
2026-09-14 22:38:34	2026-08	N211280-001	7423050	2028-02-17	U-1719	Drug substance, Drug product	2020-02-25	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N211280-001	12257246	2030-07-07	U-2718		2025-04-22	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N211280-001	11053214	2037-12-05	U-1719	Drug substance, Drug product	2021-07-28	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N211280-001	12071423	2040-07-06		Drug product	2024-09-20	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N211280-002	7423050	2028-02-17	U-1719	Drug substance, Drug product	2020-02-25	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N211280-002	12257246	2030-07-07	U-2718		2025-04-22	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N211280-002	11053214	2037-12-05	U-1719	Drug substance, Drug product	2021-07-28	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N211280-002	12071423	2040-07-06		Drug product	2024-09-20	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N211280-003	7423050	2028-02-17	U-1719	Drug substance, Drug product	2021-07-28	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N211280-003	12257246	2030-07-07	U-2718		2025-04-22	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N211280-003	11053214	2037-12-05	U-1719	Drug substance, Drug product	2021-07-28	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N211280-001	7423050	2028-02-17	U-1719	Drug substance, Drug product	2020-02-25	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N211280-001	12257246	2030-07-07	U-2718		2025-04-22	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N211280-001	11053214	2037-12-05	U-1719	Drug substance, Drug product	2021-07-28	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N211280-001	12071423	2040-07-06		Drug product	2024-09-20	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N211280-002	7423050	2028-02-17	U-1719	Drug substance, Drug product	2020-02-25	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N211280-002	12257246	2030-07-07	U-2718		2025-04-22	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N211280-002	11053214	2037-12-05	U-1719	Drug substance, Drug product	2021-07-28	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N211280-002	12071423	2040-07-06		Drug product	2024-09-20	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N211280-003	7423050	2028-02-17	U-1719	Drug substance, Drug product	2021-07-28	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N211280-003	12257246	2030-07-07	U-2718		2025-04-22	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N211280-003	11053214	2037-12-05	U-1719	Drug substance, Drug product	2021-07-28	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N211280-001	7423050	2028-02-17	U-1719	Drug substance, Drug product	2020-02-25	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N211280-001	12257246	2030-07-07	U-2718		2025-04-22	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N211280-001	11053214	2037-12-05	U-1719	Drug substance, Drug product	2021-07-28	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N211280-001	12071423	2040-07-06		Drug product	2024-09-20	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N211280-002	7423050	2028-02-17	U-1719	Drug substance, Drug product	2020-02-25	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N211280-002	12257246	2030-07-07	U-2718		2025-04-22	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N211280-002	11053214	2037-12-05	U-1719	Drug substance, Drug product	2021-07-28	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N211280-002	12071423	2040-07-06		Drug product	2024-09-20	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N211280-003	7423050	2028-02-17	U-1719	Drug substance, Drug product	2021-07-28	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N211280-003	12257246	2030-07-07	U-2718		2025-04-22	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N211280-003	11053214	2037-12-05	U-1719	Drug substance, Drug product	2021-07-28	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N211280-001	7423050	2028-02-17	U-1719	Drug substance, Drug product	2020-02-25	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N211280-001	12257246	2030-07-07	U-2718		2025-04-22	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N211280-001	11053214	2037-12-05	U-1719	Drug substance, Drug product	2021-07-28	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N211280-001	12071423	2040-07-06		Drug product	2024-09-20	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N211280-002	7423050	2028-02-17	U-1719	Drug substance, Drug product	2020-02-25	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N211280-002	12257246	2030-07-07	U-2718		2025-04-22	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N211280-002	11053214	2037-12-05	U-1719	Drug substance, Drug product	2021-07-28	`31067a03dcf5…`

Observed Orange Book exclusivity history#

Exclusivity history page 1 of 3 · 101 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Exclusivity code	Expiration	Source SHA-256
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N211280-001	NCE	2025-01-31	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N211280-002	NCE	2025-01-31	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N211280-003	NCE	2025-01-31	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N211280-001	NCE	2025-01-31	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N211280-002	NCE	2025-01-31	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N211280-003	NCE	2025-01-31	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N211280-001	NCE	2025-01-31	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N211280-002	NCE	2025-01-31	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N211280-003	NCE	2025-01-31	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N211280-001	NCE	2025-01-31	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N211280-002	NCE	2025-01-31	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N211280-003	NCE	2025-01-31	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N211280-001	NCE	2025-01-31	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N211280-002	NCE	2025-01-31	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N211280-003	NCE	2025-01-31	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N211280-001	NCE	2025-01-31	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N211280-002	NCE	2025-01-31	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N211280-003	NCE	2025-01-31	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N211280-001	NCE	2025-01-31	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N211280-002	NCE	2025-01-31	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N211280-003	NCE	2025-01-31	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N211280-001	NCE	2025-01-31	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N211280-002	NCE	2025-01-31	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N211280-003	NCE	2025-01-31	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	N211280-001	NCE	2025-01-31	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N211280-002	NCE	2025-01-31	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N211280-003	NCE	2025-01-31	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N211280-001	NCE	2025-01-31	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N211280-002	NCE	2025-01-31	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N211280-003	NCE	2025-01-31	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N211280-001	NCE	2025-01-31	`301d65b070ca…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N211280-002	NCE	2025-01-31	`301d65b070ca…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N211280-003	NCE	2025-01-31	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N211280-001	NCE	2025-01-31	`1e350fbaab3a…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N211280-002	NCE	2025-01-31	`1e350fbaab3a…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N211280-003	NCE	2025-01-31	`1e350fbaab3a…`
2024-05-31 18:47 UTC	2024-05	N211280-001	NCE	2025-01-31	`8072bd15b7f6…`
2024-05-31 18:47 UTC	2024-05	N211280-002	NCE	2025-01-31	`8072bd15b7f6…`
2024-05-31 18:47 UTC	2024-05	N211280-003	NCE	2025-01-31	`8072bd15b7f6…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N211280-001	NCE	2025-01-31	`5c6f7cd8ea54…`

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

Additional Listing Data#

Finished product: Yes
Brand name base: Reyvow

Active Ingredients#

Ingredient, Strength table
Ingredient	Strength
LASMIDITAN	100 mg/1

Harmonized UNII identifiers#

UNII identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
Identifier	FDA.report destination
760I9WM792	Internal UNII lookup

Harmonized RxCUI identifiers#

RxCUI identifiers page 1 of 1 · 4 matching rows.

Identifier, FDA.report destination table
Identifier	FDA.report destination
2256937	Internal RxNorm lookup
2256943	Internal RxNorm lookup
2256945	Internal RxNorm lookup
2256947	Internal RxNorm lookup

Harmonized SPL set identifiers#

SPL set identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
Identifier	FDA.report destination
aea3358c-ff41-4490-9e6d-c7bf7b3de13f	Available on FDA.report

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
362d7abb-94e6-4c60-9a58-266894157713	Product name	1	20231023
1a6a30a3-3b1f-4e9d-baa3-be148e037910	Product name	1	20200305
816b97af-edc5-4060-aff1-b814bdbcad50	Product name	1	20190415
419aab54-5d5a-4146-9453-026d4a9991be	Product name	2	20170525
89dac932-b90a-4410-9ab1-84c53e57de25	Product name	1	20150316
d723478e-ad4a-ec23-6bd7-cfe33e1e3840	Product name	1	20140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	SPL version
0002-4491-08	Reyvow	4 in 1 BLISTER PACK	TABLET	4	15
0002-4491-08	Reyvow	2 in 1 CARTON	TABLET	2	15
0002-4491-61	Reyvow	1 in 1 CARTON	TABLET	1	15
0002-4491-61	Reyvow	4 in 1 BLISTER PACK	TABLET	4	15
0002-4491-62	Reyvow	2 in 1 BLISTER PACK	TABLET	2	15
0002-4491-62	Reyvow	1 in 1 CARTON	TABLET	1	15

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
0002-4491-08	EA - Each	0002-4491	74daeacb-4784-477c-8ea9-fdf3f8e60220	1	2020-02-13

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
0002-4491	REYVOW (LASMIDITAN) TABLET [ELI LILLY AND COMPANY]	15	Current NDC, Legacy NDC, 6 package rows	20241215_aea3358c-ff41-4490-9e6d-c7bf7b3de13f.zip

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Reyvow	LASMIDITAN	Eli Lilly and Company	aea3358c-ff41-4490-9e6d-c7bf7b3de13f	2026-01-08	Warnings, Adverse reactions	Exact identifier application applno (NDA): 211280 application number: NDA211280 ndc (package): 0002-4491-61 ndc (product): 0002-4491 ndc11 (package): 00002449161

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
760I9WM792	LASMIDITAN	439239-90-4	LASMIDITAN

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	DailyMed	SPL version
2256937	lasmiditan 100 MG Oral Tablet	PSN	aea3358c-ff41-4490-9e6d-c7bf7b3de13f	15
2256945	lasmiditan 50 MG Oral Tablet	PSN	aea3358c-ff41-4490-9e6d-c7bf7b3de13f	15
2256943	REYVOW 100 MG Oral Tablet	PSN	aea3358c-ff41-4490-9e6d-c7bf7b3de13f	15
2256947	REYVOW 50 MG Oral Tablet	PSN	aea3358c-ff41-4490-9e6d-c7bf7b3de13f	15
2256943	lasmiditan 100 MG Oral Tablet [Reyvow]	SBD	aea3358c-ff41-4490-9e6d-c7bf7b3de13f	15
2256947	lasmiditan 50 MG Oral Tablet [Reyvow]	SBD	aea3358c-ff41-4490-9e6d-c7bf7b3de13f	15
2256937	lasmiditan 100 MG Oral Tablet	SCD	aea3358c-ff41-4490-9e6d-c7bf7b3de13f	15
2256945	lasmiditan 50 MG Oral Tablet	SCD	aea3358c-ff41-4490-9e6d-c7bf7b3de13f	15
2256943	Reyvow 100 MG Oral Tablet	SY	aea3358c-ff41-4490-9e6d-c7bf7b3de13f	15
2256947	Reyvow 50 MG Oral Tablet	SY	aea3358c-ff41-4490-9e6d-c7bf7b3de13f	15

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Units	Marketing start	Marketing end	Sample	Exclude flag	Status
0002-4491-61	00002449161	1 BLISTER PACK in 1 CARTON (0002-4491-61) > 4 TABLET in 1 BLISTER PACK	1 blister pack	2020-01-31	0000-00-00	Yes	No	Current